Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan, US, Europe Anti-Infective Agent Markets Grow 48.4% in FY2014 Driven by Anti-HCV Treatments: Survey
July 7, 2015
- Foreign Drug Makers’ Sales Dip on Generic Inroads in 2014
July 6, 2015
- Multiple Myeloma Treatment Farydak Approved: Novartis
July 6, 2015
- Once-Weekly GLP-1 Receptor Agonist Trulicity Approved: Eli Lilly Japan
July 6, 2015
- Idiopathic Pulmonary Fibrosis Treatment OFEV Approved: NBI
July 6, 2015
- Immune Checkpoint Inhibitor Yervoy Approved for Malignant Melanoma: Bristol-Myers
July 6, 2015
- Lupus Erythematosus Treatment Plaquenil Approved: Sanofi
July 6, 2015
- Hepatitis C Treatment Harvoni Approved: Gilead Sciences
July 6, 2015
- MTPC Preparing to Submit Radicut for an Indication of ALS in the US
July 3, 2015
- Santen Files IND Application for Anti-Endoglin Antibody for Wet AMD in US
July 3, 2015
- President Tada to Double as Drug Development Head: Sumitomo Dainippon
July 3, 2015
- JCR Aims at Growth through New Products, Out-Licensing Activities
July 2, 2015
- Merck Serono, Nippon Shinyaku to Copromote Gonalef
July 2, 2015
- Announcement: 2nd Annual Oncology Asia - Sheraton Miyako Hotel Tokyo, September 7-9
July 2, 2015
- Bayer Files for Regulatory Approval of Hemophilia A Treatment in Japan
July 1, 2015
- Daiichi Sankyo Acquires Additional Shares in Kitasato Daiichi Sankyo Vaccine for 10 Billion Yen
July 1, 2015
- Febuxostat Approved for Hyperuricemia Associated with Cancer Chemotherapy in Europe: Teijin Pharma
July 1, 2015
- Taisho, Ablynx of Belgium to Collaborate for Development and Commercialization of Anti-TNF-α Nanobody
July 1, 2015
- Otsuka Initiates Voluntary Recall of Uniphyl
June 30, 2015
- Takecab Slips to 2nd Place as Suglat Comes 1st in GP Market in May: Anterio Ranking
June 30, 2015
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…